<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3074">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04373798</url>
  </required_header>
  <id_info>
    <org_study_id>APPI2-CV-2020-02</org_study_id>
    <nct_id>NCT04373798</nct_id>
  </id_info>
  <brief_title>C-reactive Protein Levels Among Individuals With COVID-19</brief_title>
  <official_title>Triage Strategies Based on C-reactive Protein Levels Among Individuals With COVID-19: A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henning Bliddal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Frederiksberg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this multi-center study is to clarify the value of a CRP measurement
      for triage of patients initially presenting with light symptoms of the COVID-19 infection.

      Current recommendations of management of COVID-19 include large-scale tests for virus. Such
      tests reveal whether an individual is infected with the virus, however, the demonstration of
      virus per se has no prognostic value for the ensuing course of the COVID-19 disease.
      Publications of possible treatments strategies increase exponentially, while evidence of
      triage of the affected individuals is mainly based on the level of pulmonary affection as
      measured by the Oxygen saturation.

      To inform decision making for which patients are to be hospitalized due to risk of developing
      more severe affection, this study addresses the question, whether triage may be performed
      with the aid of a simple CRP measurement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalisation</measure>
    <time_frame>within 28 days</time_frame>
    <description>Admission to a hospital. Reason for admission is recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfer to Intensive Care Unit</measure>
    <time_frame>within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen treatment during hospitalisation</measure>
    <time_frame>within 28 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Suspected COVID-19</arm_group_label>
    <description>Individuals with symptoms who are seen at covid19 check points for covid19 diagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>C-reactive protein</intervention_name>
    <description>Measurement of CRP value from blood sample taken at covid19 check point (baseline).</description>
    <arm_group_label>Suspected COVID-19</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals who are COVID-19 positive at the check point test.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A test for COVID-19 taken at the check point

          2. Signed, informed consent for blood test to be drawn for the Biobank

        Exclusion Criteria:

          1. Former admission to hospital for COVID-19

          2. Direct admission from check point.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bliddal, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Parker Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henning Bliddal, DMSc</last_name>
    <phone>+4538164155</phone>
    <email>henning.bliddal@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Parker Institute, Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Bliddal, DMSc</last_name>
      <phone>+4538164151</phone>
      <email>henning.bliddal@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Line Rustad</last_name>
      <phone>0045 38164155</phone>
      <email>parker@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Henning Bliddal, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Frederiksberg University Hospital</investigator_affiliation>
    <investigator_full_name>Henning Bliddal</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

